In the Drug Evaluation entitled “Sustained-release fampridine for multiple sclerosis” by Christopher T Bever Jr & Susan IV Judge, published in the June 2008 issue of Expert Opinion on Investigational Drug (Expert Opin. Investig. Drugs (2009) 18(7):1013-1024), it has been brought to our attention that the affiliation should have read as follows:
University of Maryland Hospital, Department of Neurology, Baltimore, Maryland, USA
In addition, the last sentence of section 5.2, paragraph four should have read as follows:
The primary outcome measure was percentage change in walking speed based on the timed 25-foot walk; secondary measures included clinician global impression (CGI), subject global impression (SGI), 12-item multiple sclerosis walking scale (MSWS-12), lower extremity manual muscle testing (LEMMT), Ashworth spasticity scoring, 9-hole peg test and paced auditory serial addition task.
The authors, editors and publisher sincerely regret any inconvenience this may have caused our readers.